The Cardiac Ledger

Letters from UnifiMed on how cardiovascular technologies reach the US market: strategy, market access, clinical evidence and regulatory affairs.

All letters

  • Market Access Letter

    Breakthrough Lost Its Medicare Edge

    Since October 1, 2026, Breakthrough designation no longer exempts most devices from the substantial clinical improvement test for NTAP and pass-through. RAPID coverage is still a proposal. A 2027 plan has to carry those two facts on separate timelines.

  • Market Access Letter

    The TAVR Rule Left One Group of Patients Out

    CMS's September 10, 2026 TAVR decision covers symptomatic severe aortic stenosis without a study requirement, while asymptomatic patients are covered only in a CMS-approved study. The two timelines differ, and plans should treat them separately.

  • CEO Letter

    The Buyer Already on Your Cap Table

    In cardiovascular MedTech the early strategic investor is often the natural acquirer. The terms of a strategic round can shape how many bidders compete at exit and how proceeds divide, so they deserve the same scrutiny a board gives the valuation.

RSS feed